Site icon pharmaceutical daily

BioInvent and ThromboGenics amending long-standing monoclonal antibody development agreement

BioInvent International and ThromboGenics have agreed to amend their long-standing agreement, which covers the co-development of the novel anti-PlGF monoclonal antibody products TB-403 and THR-317.

BioInvent  said in its press release that the revisions to the existing agreement have been aligned with each company`s strategic ambitions and therapeutic focus.

The company reminded that novel anti-PIGF monoclonal antibody is currently being developed as:

According to new contractual arrangement, the spilt of economic value and costs will be as follows:

Exit mobile version